Document:

<PAGE>

                                                                   Exhibit 10.67

October 22, 1999

Alan L. Hillyard, Ph.D.
1752 Kent Place
Vista, CA 92084

Dear Alan:

We are pleased to extend you an offer of employment with Trega Biosciences,
Inc. (the "Company"). This letter shall serve to clarify the terms and
conditions of the job we are offering you.

We are offering you a full-time position as Vice President, Informatics and
Chief Information Officer, working under the direction of Michael G. Grey,
President & Chief Executive Officer of Trega. Your employment will begin on a
mutually agreed upon date with an exempt monthly salary of $15,416.67.1
Should the Company meet its annual goals you will be eligible to receive a
bonus, with a target of 50% of your annual salary.

You will be eligible to participate in the Company's health-care benefit
plans on the first of the month following your hire date and in the Company's
401 (k) Retirement Plan during the first enrollment period following your
date of hire. You will begin accruing vacation at a rate of 15 days per year
which you will be eligible to take as it is accrued. Further, as part of
Trega's holiday leave policy, you will receive five (5) additional days of
leave between the Christmas and New Year's holidays. Subject to the approval
of the Compensation Committee on October 29, 1999, you will be granted an
option to acquire 150,000 shares of stock at an exercise price equal to the
closing price of Trega common stock on such date. The option is subject to
the terms of the Option Agreement, the 1996 Stock Incentive Plan and your
written acceptance of this offer letter on or before October 28, 1999.

You acknowledge that as a condition of employment you will be required to
execute a Confidentiality Agreement and any and all other documents
reasonably required by the Company to protect its proprietary trade secrets
from disclosure and to prevent the unauthorized use by the Company of any
proprietary trade secrets of other parties or entities. These documents are
attached to this letter as Exhibit A and are incorporated into this letter by
reference.

-----------------------
1Please be advised that this offer is contingent on your completing an I-9 form
and submitting support information regarding your right to work in the United
States within three days of hire.

<PAGE>

Alan L. Hillyard, Ph.D.
October 22, 1999
Page 2

You acknowledge and agree that in accordance with California law, your
employment with the Company is "at will" and you understand that the Company
or you may terminate your employment at any time, for any reason whatsoever,
with or without cause and with or without notice. The Company also reserves
the right to make personnel decisions regarding your employment, including
but not limited to discussions regarding any promotion, salary adjustment,
transfer or disciplinary action, up to and including termination, consistent
with the needs of the business. You shall be entitled to receive a severance
payment equal to six months' salary in the event that you are terminated
without cause within 180 days following any of: (i) the filing by the
Company of a voluntary petition for reorganization or dissolution under the
U.S. bankruptcy laws; (ii) the filing against the Company of an involuntary
petition, not promptly dismissed or bonded over, seeking dissolution of the
Company under the U.S. bankruptcy laws, or (iii) a "change in control" of the
Company where "change in control" means (a) the sale of all or substantially
all of the Company's assets in a single transaction or a series of related
transactions to an unaffiliated party, (b) the acquisition in a single
transaction or a series of related transactions by an unaffiliated party of a
majority of the Company's voting securities, or (c) the merger of the Company
with another unaffiliated entity following which the shareholders of the
Company prior to the transaction shall come to hold, by virtue of the merger
transaction, fewer than a majority of the voting securities of the merged
entity.

You and the Company further agree that all disputes, claims or causes of
action arising out of or relating to your employment or its termination,
shall be submitted to binding arbitration before a neutral arbitrator, except
where the law specifically forbids the use of arbitration as a final and
binding remedy (See Exhibit B).

Alan, my colleagues and I look forward to your joining our organization. We
are pleased to have someone of your expertise and leadership assist in the
facilitation of Trega's continued growth and success. I would like to do
whatever I can over the next few days to facilitate a quick, but informed
decision on your part. Please do not hesitate to contact me either at work,
(858) 410-6631 or home at (858) 509-9648. If this letter accurately reflects
our agreement and your acceptance of these terms, please sign one copy and
return it to me by Thursday, October 28, 1999. The other copy is for your
records.

Sincerely,

/s/ Michael J. Green
Michael J. Green, Ph.D.
Vice President, Drug Discovery
For Michael G. Grey,
Chief Executive Officer

<PAGE>

Alan L. Hillyard, Ph.D.
October 22, 1999
Page 3

                                 ACKNOWLEDGMENT

I agree to the terms and conditions of employment set forth in this letter.

/s/ Alan Hillyard                                              October 26, 1999
-----------------------------                                  ----------------
Alan Hillyard, Ph.D.                                           Date<PAGE>

CONFIDENTIAL TREATMENT REQUESTED                                   EXHIBIT 10.73

CONFIDENTIAL TREATMENT REQUESTED: PAGES WHERE CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED ARE MARKED "CONFIDENTIAL TREATMENT REQUESTED" AND APPROPRIATE
SECTIONS, WHERE TEXT HAS BEEN OMITTED, ARE NOTED WITH "[CONFIDENTIAL TREATMENT
REQUESTED]." AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION.

                             LIBRARY SALES AGREEMENT

         THIS LIBRARY SALES AGREEMENT dated as of December 8, 1999 (the
"Agreement"), is entered into between TREGA BIOSCIENCES, INC., a Delaware
corporation ("Trega"), having a place of business at 9880 Campus Point Drive,
San Diego, California 92121 and Evotec BioSystems AG ("Purchaser"), a German
corporation having a place of business at Schnackenburgallee 114, 22525 Hamburg
Germany.

The parties intending to be legally bound hereby agree as follows:

                                   ARTICLE 1

                                  DEFINITIONS

The following capitalized terms used in this Agreement shall have the following
meaning:

         1.1 "AFFILIATE" means, with respect to any person, any other person
which directly or indirectly controls, is controlled by, or is under common
control with, such person. A person shall be regarded as in control of another
person if it owns, or directly or indirectly controls, more than fifty percent
(50%) of the voting stock or other ownership interest of the other person, or if
it directly or indirectly possesses the power to direct or cause the direction
of the management and policies of the other person.

         1.2 "[CONFIDENTIAL TREATMENT REQUESTED]" means all patents and patent
applications claiming [CONFIDENTIAL TREATMENT REQUESTED] used to create Trega
Materials.

         1.3 "BUILDING BLOCKS" means the organic chemical component molecules
that when combined form a combinatorial library of organic chemical compounds.

         1.4 "CLIENT" means a Third Party to whom Purchaser agrees to provide
Screening Services on a target provided by such Third Party in exchange for a
fee but excludes Purchaser's Partners.

         1.5 "CLIENT ACCESS FEE" means the fees payable by Client for Screening
Services in respect of biological targets against Trega Materials pursuant to
Article 3.2 and Exhibit C.

         1.6 "COMBINATORIAL LIBRARY" means the physical samples of that portion
of a Virtual Combinatorial Library which is synthesized by Trega for use in its
organic chemical compound supply business.

         1.7 "CONFIDENTIAL INFORMATION" means all confidential proprietary
information of a Party that, if disclosed in a nontangible medium, is identified
as being confidential or that, if disclosed in a tangible medium, is marked as
being confidential.

<PAGE>

CONFIDENTIAL TREATMENT REQUESTED

         1.8 "CUSTOMER" means a Third Party to whom Purchaser provides Screening
Services on a target provided by such Third Party in respect of Trega Materials
including without limitation Clients and Purchaser's Partners.

         1.9 "EFFECTIVE DATE" means the date of this Agreement.

         1.10 "PACKAGING PROTOCOL" means the protocol pursuant to Article 2.4 or
such other packaging protocol as the parties may agree in writing from time to
time.

         1.11 "PARTY" means Purchaser and/or Trega.

         1.12 "PRODUCT" means a product which contains, incorporates, uses, is
the result of, is a chemical or biological derivative of, is based upon, is
derived directly or indirectly from or by use of, or is a by-product of a Subset
Library Compound which would have not been discovered but for use of such Subset
Library Compound. "Product" shall not include any product that was developed or
derived independently of Trega Materials.

         1.13 "PURCHASER'S PARTNER" means a Third Party with whom Purchaser
enters into an agreement to work exclusively with such Third Party in conducting
research in a particular field and/or Purchaser's drug development and/or drug
discovery partners.

         1.14 "QUARTER" the quarterly periods ending 31st March, 30th June, 30th
September and 31st December;

         1.15 "SCREENING SERVICES" means the Purchaser's proprietary high
throughput screening services conducted for a Customer on such Customer's
target.

         1.16 "SUBSET LIBRARY" means a portion of a Combinatorial Library.

         1.17 "[CONFIDENTIAL TREATMENT REQUESTED]" means, with respect to Trega
Materials delivered to Purchaser hereunder, a detailed description of the
know-how necessary for a skilled, [CONFIDENTIAL TREATMENT REQUESTED] to create
compounds contained within such Trega Materials, but specifically excluding
[CONFIDENTIAL TREATMENT REQUESTED].

         1.18 "[CONFIDENTIAL TREATMENT REQUESTED]" means the intellectual
property rights (including without limitation know how, trade secrets,
copyrights and database rights) in the [CONFIDENTIAL TREATMENT REQUESTED].

         1.19 "SUBSET LIBRARY COMPOUND" means a compound contained within a
Subset Library.

         1.20 "THIRD PARTY" means any person other than the Parties.

         1.21 "TREGA MATERIALS" means Subset Libraries and Subset Library
Compounds delivered to Purchaser pursuant to this Agreement.

                                      -2-

<PAGE>

CONFIDENTIAL TREATMENT REQUESTED

         1.22 "TREGA PATENTS" means all patents and patent applications used to
create a Combinatorial Library including any provisional applications, priority
applications, divisionals, continuations, continuations-in-part, reissues,
reexaminations, supplemental protection certificates and the like, renewals, and
extensions which are owned by, licensed to, or controlled by Trega, as of the
Effective Date, or as to which Trega acquires ownership or control at any time
during the term of this Agreement, where ownership or control includes a right
to grant licenses thereto [CONFIDENTIAL TREATMENT REQUESTED].

         1.23 "TEA-BAG PATENTS" means the following patents and patent
applications including any provisional applications, priority applications,
divisionals, continuations, continuations-in-part, reissues, reexaminations,
supplemental protection certificates and the like, renewals, and extensions:
U.S. Patent 4,631,211, and its foreign counterparts.

         1.24 "VIRTUAL COMBINATORIAL LIBRARY" means a [CONFIDENTIAL TREATMENT
REQUESTED] collection of organic chemical compounds determined by Trega to be
chemically feasible. Such compounds comprise [CONFIDENTIAL TREATMENT REQUESTED].

                                   ARTICLE 2

                         COMPOUND PURCHASE PROVISIONS

         2.1 SUPPLY OF SUBSET LIBRARIES TO PURCHASER.

             2.1.1 As at the Effective Date Trega has synthesized or is in the
process of synthesizing [CONFIDENTIAL TREATMENT REQUESTED] Subset Libraries
comprising approximately [CONFIDENTIAL TREATMENT REQUESTED]. Purchaser shall
purchase such Subset Libraries from Trega and Trega shall, subject to
determination of the Packaging Protocol pursuant to Article 2.4, deliver such
Subset Libraries to Purchaser as follows:

                              2.1.1.1 within 30 days of the Effective Date Trega
shall ship Purchaser [CONFIDENTIAL TREATMENT REQUESTED] Subset Libraries; and

                              2.1.1.2 by no later than [CONFIDENTIAL TREATMENT
REQUESTED] Trega shall ship Purchaser [CONFIDENTIAL TREATMENT REQUESTED]
additional Subset Libraries.

             2.1.2 In the period to [CONFIDENTIAL TREATMENT REQUESTED] Trega
shall offer Purchaser a minimum of [CONFIDENTIAL TREATMENT REQUESTED] further
Subset Libraries.

             2.1.3 None of the Subset Libraries offered under Article 2.1.1
and 2.1.2 shall contain less than [CONFIDENTIAL TREATMENT REQUESTED] Subset
Library Compounds and not more than [CONFIDENTIAL TREATMENT REQUESTED] of the
Subset Libraries offered to Purchaser under Article 2.1.1 and 2.1.2 shall
contain more than [CONFIDENTIAL TREATMENT REQUESTED] Subset Library Compounds.

                                      -3-

<PAGE>

CONFIDENTIAL TREATMENT REQUESTED

         2.2 MINIMUM PURCHASE. Purchaser shall purchase from Trega a minimum of
[CONFIDENTIAL TREATMENT REQUESTED] Subset Library Compounds by no later than
[CONFIDENTIAL TREATMENT REQUESTED] and, for the avoidance of doubt, the Subset
Library Compounds purchased by Purchaser pursuant to Article 2.1.1 shall count
towards such minimum purchase. Purchase of Subset Library Compounds in excess of
[CONFIDENTIAL TREATMENT REQUESTED] shall be at the absolute discretion of
Purchaser.

         2.3 GENERAL TERMS FOR SUPPLY OF TREGA MATERIALS. Trega shall supply
Trega Materials to Purchaser according to the following terms and conditions:

             2.3.1 The supply of Trega Materials to Purchaser is governed by
the terms of this Agreement. None of the terms or conditions of any order,
invoice, confirmation or similar instrument is applicable, except those
specifying quantity ordered, delivery date, designated carrier and insurance
information.

             2.3.2 Purchaser shall order Trega Materials in writing save that
on the Effective Date the Purchaser shall be deemed to have placed a firm order
for the Subset Library Compounds referred to in Article 2.1.1. Trega shall ship
Trega Materials (other than the Subset Library Compounds referred to in Article
2.1.1) to Purchaser within 60 days of the date of order.

             2.3.3 All Trega Materials will be shipped F.C.A (as defined in
Incoterms 1990). Trega's place of manufacture. Trega shall invoice Purchaser for
all reasonable shipping and insurance charges. The risk of loss and damage to
Trega Materials passes to Purchaser upon release to Purchaser's designated
carrier or, in the absence of such designation by Purchaser, to a carrier
designated by Trega. At the time each Trega Material is released to Purchaser's
designated carrier, Trega shall send to Purchaser a release memo and release
information detailing the Trega Materials shipped and the date of shipping.

         2.4 PACKAGING. [CONFIDENTIAL TREATMENT REQUESTED]. Trega shall package
all Trega Materials to be delivered under this Agreement in accordance with the
Packaging Protocol.

         2.5 INSPECTION AND ACCEPTANCE. Purchaser shall inspect Trega Materials
within [CONFIDENTIAL TREATMENT REQUESTED] receipt thereof by Purchaser.
Purchaser shall accept Trega Materials which pass [CONFIDENTIAL TREATMENT
REQUESTED].

         2.6 [CONFIDENTIAL TREATMENT REQUESTED]. On delivery of each consignment
of Trega Materials to Purchaser Trega shall provide Purchaser with [CONFIDENTIAL
TREATMENT REQUESTED] for such Trega Materials in written format similar to that
of peer reviewed journals

                                      -4-

<PAGE>

CONFIDENTIAL TREATMENT REQUESTED

         2.7 DELIVERY OF VIRTUAL COMBINATORIAL LIBRARIES. Delivery shall be in
[CONFIDENTIAL TREATMENT REQUESTED] or a reasonable alternative as determined by
Trega.

         2.8 REPORTS. Purchaser shall notify Trega in writing when a Product is
planned to be the subject of a of a public disclosure, including, but not
limited to, a publication, presentation, or press release. These disclosures are
not required to disclose the biological target of the Product. Notification by
Purchaser to Trega in respect of Products of Purchaser's Customers shall be
subject to Purchaser obtaining the relevant Customer's consent thereto.

         2.9 DEVELOPMENT PLANS. Trega shall keep Purchaser fully informed of
Trega's plans for the synthesis of new Combinatorial Libraries, including
without limitation details of the chemistries planned to be synthesized and the
timing thereof.

                                   ARTICLE 3

                                   LICENSES

         3.1 TECHNOLOGY GRANT. Trega hereby grants to Purchaser:

             3.1.1 a world-wide, irrevocable, royalty-free, sublicensable,
non-exclusive license under the Trega Patent to make, have made, use, offer for
sale, import and sell Products synthesized or derived directly or indirectly
from, or by use of, Trega Materials; and

             3.1.2 [CONFIDENTIAL TREATMENT REQUESTED].

         3.2 COMPOUND STRUCTURES. Following the provision of Screening Services
to a Customer in respect of any Trega Material, Purchaser shall be entitled to
disclose the compound structure of the Subset Library Compound to the Customer.

         3.3 CLIENT ACCESS FEES Purchaser shall charge each Client a Client
Access Fee in respect of each Trega Material screened in a primary or initial
screen against a target by Purchaser for the Client. Such Client Access Fee
shall be calculated in accordance with Exhibit C to this Agreement. Purchaser
shall impose on Clients in respect of Client Access Fees a payment period
[CONFIDENTIAL TREATMENT REQUESTED] from the completion of the relevant screening
program and shall pay all Client Access Fees received by it to Trega. Purchaser
shall take normal commercial steps to chase late payments of Client Access Fees
including, without limitation, such steps as Purchaser routinely takes to
recover debts owed to it. In no circumstances shall Purchaser be liable to make
up any shortfall in payments of Client Access Fees by Clients.

                                      -5-

<PAGE>

CONFIDENTIAL TREATMENT REQUESTED

         3.4 TECHNOLOGY GRANT EXCEPTION. The rights and licenses granted by this
Agreement, including those arising from the purchase of Trega Materials
specifically exclude the right to:

             3.4.1 [CONFIDENTIAL TREATMENT REQUESTED];

             3.4.2 Evaluate, investigate or characterize Trega Materials or
Products for purposes of establishing their direct effects on [CONFIDENTIAL
TREATMENT REQUESTED]; provided, however, Purchaser may evaluate, investigate, or
characterize Trega Materials and Products that have indirect effects on
[CONFIDENTIAL TREATMENT REQUESTED];

             3.4.3 Make, have made, use, sell, offer for sale, or import
Products that result from the activities prohibited in Articles 3.4.1 and 3.4.2
above; or

             3.4.4 Sell or offer to sell to Third Parties a Combinatorial
Library in competition with Trega's combinatorial library business always
provided that Purchaser may:

                   3.4.4.1 sell, otherwise provide or offer to sell or
otherwise provide Trega Materials to Third Parties in conjunction with
Screening Services or following the provision of Screening Services in
respect of the relevant Trega Materials; and

                   3.4.4.2 sell, otherwise provide or offer to sell or
otherwise provide selections of any Trega Materials to Third Parties
following screening of such Trega Materials by Purchaser alone or screening
of such Trega Materials by Purchaser in conjunction with any Purchaser's
Partner.

                   3.4.4.3 purchase organic chemical compounds from third
party combinatorial chemistry providers and/or develop its own combinatorial
chemistries.

         3.5 MARKETING. Each Party shall use its reasonable endeavors to itself
market and to support the marketing by the other Party of Purchaser's Screening
Services in respect of the Trega Materials and in particular but without
limitation:

             3.5.1 Trega shall, at its own expense, produce and provide to
Purchaser free of charge sufficient promotional materials (including without
limitation brochures and leaflets) promoting Trega Materials.

             3.5.2 Purchaser shall, at its own expense, produce and provide to
Trega free of charge sufficient promotional materials (including without
limitation brochures and leaflets) promoting the Screening Services in respect
of Trega Materials.

                                      -6-

<PAGE>

CONFIDENTIAL TREATMENT REQUESTED

             3.5.3 Each Party agrees that it will use the other Party's
promotional material provided pursuant to this Article 3.4 in the promotion of
Purchaser's Screening Services in respect of the Trega Materials but not
otherwise.

             3.5.4 Each Party agrees that it shall not modify the other's
promotional materials without the other's prior written consent.

             3.5.5 Each Party agrees to consult with the other and provide the
other with information and assistance in connection with the use of the other's
promotional materials.

             3.5.6 Neither Party shall publish or distribute promotional
materials featuring the other Party's name or trade marks or otherwise use the
other Party's name or trade marks without having first obtained the other
Party's prior written approval of a sample of such promotional materials or, as
appropriate, the nature and form of the intended use.

                                   ARTICLE 4

                              PAYMENT OBLIGATIONS

         4.1 PAYMENTS FOR SUBSET LIBRARIES. Purchaser shall pay to Trega a sum
calculated in accordance with Exhibit C for each Trega Material delivered.

         4.2 PAYMENT METHOD. Upon shipment of any Trega Material to Purchaser
under this Agreement, Trega shall submit an invoice to Purchaser, and Purchaser
shall pay each invoice in full within thirty (30) days of receipt and acceptance
of both the Trega Material and the associated [CONFIDENTIAL TREATMENT
REQUESTED]. Purchaser shall make all payments to Trega under this Agreement in
United States dollars by check or by bank wire transfer in immediately available
funds to an account designated by Trega, on or before the date on which such
payments are due.

         4.3 LATE PAYMENTS. Unless otherwise provided in this Agreement,
Purchaser shall pay interest to Trega on the aggregate amount of any payments
that are not paid on or before the date the payments are due under this
Agreement, at an annual rate equal to the prime rate of interest as reported by
Bank of America NT&SA in San Francisco, California, from time to time plus
[CONFIDENTIAL TREATMENT REQUESTED] or any lower maximum rate allowable by law.

         4.4 TAXES AND OTHER CHARGES. Purchaser shall pay all federal, state,
county or municipal sales or use taxes, excise or similar charges (other than
taxes that may be assessed on the income of Trega), assessed or charged in
connection with the purchase of the Trega Materials according to this Agreement.

                                      -7-

<PAGE>

CONFIDENTIAL TREATMENT REQUESTED

         4.5 Payment of Client Access Fees.

             4.5.1 Within [CONFIDENTIAL TREATMENT REQUESTED] of the end of
each Quarter Purchaser shall:

                   4.5.1.1 provide Trega with a financial statement for that
Quarter setting out the Client Access Fees received by it pursuant to
Article 3.3 in respect of such Quarter;

                   4.5.1.2 pay the Client Access Fees received by it in such
Quarter to Trega.

             4.5.2 Purchaser shall keep at its normal place of business
records and books of account sufficient to verify the accuracy of the
statements provided pursuant to Article 4.5.1.1.

             4.5.3 Purchaser shall make its records and books available for
inspection during normal business hours by an independent professional
accountant appointed by Trega and reasonably acceptable to Purchaser for the
sole purpose of verifying the accuracy of any statement provided by Purchaser to
Trega pursuant to Article 4.5.1.1 provided that such accountant executes
Purchaser's non-disclosure agreement.

             4.5.4 Trega shall be entitled to have inspections carried out
pursuant to Article 4.5.2 not more than once in any period of [CONFIDENTIAL
TREATMENT REQUESTED] on giving Purchaser [CONFIDENTIAL TREATMENT REQUESTED]
written notice prior to each inspection.

                                   ARTICLE 5

                         OPTIONAL PRODUCTS OR SERVICES

         5.1 Trega shall if so requested by Purchaser provide to Purchaser those
additional products and services described in Optional Products and Services in
Exhibit B on the terms and conditions set out in Exhibit B.

                                   ARTICLE 6

                                CONFIDENTIALITY

         6.1 CONFIDENTIAL INFORMATION. For purposes of Article 6, a Party
communicating Confidential Information shall be referred to as the "Disclosing
Party" and the Party receiving the Confidential Information shall be referred to
as the "Recipient Party." During the term of this Agreement, and until the fifth
anniversary following the expiration or earlier termination hereof, the
Recipient Party shall maintain in confidence all Confidential Information of the
Disclosing Party. Recipient Party shall not use, disclose or grant the use of
the Confidential Information except on a need-to-know basis to those directors,
officers, Affiliates, employees, collaborators, consultants, clinical
investigators or contractors (and, in the case of Purchaser, Customers) of the
Recipient Party, to the extent

                                      -8-

<PAGE>

such disclosure is reasonably necessary in connection with the Recipient Party's
activities as expressly authorized by this Agreement. To the extent that
disclosure is authorized by this Agreement, prior to disclosure, each Party
shall obtain agreement of any person to whom Confidential Information will be
disclosed to hold such Confidential Information in confidence in accordance with
this Article 6 and not make use of the Confidential Information for any purpose
other than that permitted by this Agreement.

         6.2 PERMITTED DISCLOSURES. The confidentiality obligations contained in
Article 6.1 above do not apply to the extent that:

             6.2.1 any Recipient Party is required (i) to disclose information
by law, order or regulation of a governmental agency or a court of competent
jurisdiction, or (ii) to disclose information to any governmental agency for
purposes of obtaining approval to test or market a product or obtain patent
protection, provided in either case that, where practicable, the Recipient shall
provide written notice thereof to the other Party; or

             6.2.2 the Recipient Party can demonstrate that (i) the disclosed
information was public knowledge at the time of its disclosure to the Recipient
Party, or thereafter became public knowledge, other than as a result of actions
of the Recipient Party in violation of this section 6; (ii) the disclosed
information was rightfully known by the Recipient Party or any of its Affiliates
(as shown by its written records) prior to the date of disclosure to the
Recipient Party or any of its Affiliates by the Disclosing Party hereunder;
(iii) the disclosed information was disclosed to the Recipient Party or any of
its Affiliates from a source unrelated to any Party to this Agreement and not
under a duty of confidentiality to the Disclosing Party; or (iv) the disclosed
information was independently developed by the Recipient Party or any of its
Affiliates without such Confidential Information as shown through reasonable
documentary evidence thereof.

         6.3 ANNOUNCEMENTS.

             6.3.1 Purchaser and Trega hereby agree to publicly disclose the
signing of this Agreement by means of a joint announcement, the timing and
content of which shall be agreed in advance by both Parties. In addition,
following public disclosure by Purchaser of matters pertaining to the
development, regulatory approval, or commercialization of Products, Trega shall
be entitled to publicly announce that those Products were derived from Trega
Materials, always provided that any Customer of Purchaser associated therewith
has given its prior consent to such announcement.

             6.3.2 Trega shall ensure that any announcement pursuant to
Article 6.3.1 does not disclose the identity of any compounds or the targets at
which the compounds are directed, unless the Purchaser and any relevant Customer
has agreed otherwise. Purchaser and any relevant Customer shall have the right
to review and amend the contents of such announcements prior to their being made
to the extent that they pertain to Purchaser, the Product and/or any Customer,
and such review and amendment shall be effected within a reasonable period.

                                      -9-

<PAGE>

CONFIDENTIAL TREATMENT REQUESTED

             6.3.3 The Parties acknowledge that this Agreement may be filed
with the U.S. Securities and Exchange Commission in satisfaction of Trega's
responsibilities as a public company. Purchaser shall be given an opportunity to
review any redacted version of this Agreement to be filed and shall provide its
comments within a reasonable period of time, being not less than [CONFIDENTIAL
TREATMENT REQUESTED].

             6.3.4 Save as provided in this Article 6.3 and Article 3.5 and in
the absence of specific agreement between the parties, neither Party shall
originate any publicity, news release or public announcement, written or oral,
whether to the public or press, relating to this Agreement including but not
limited to performance under it or any dispute in relation to it always provided
that either party may disclose the existence of this Agreement and the name of
the other party in connection therewith.

                                   ARTICLE 7

                                    PATENTS

         7.1 INFRINGEMENT.

             7.1.1 [CONFIDENTIAL TREATMENT REQUESTED]

             7.1.2 If either Party receives a claim or assertion or otherwise
becomes aware that practice of the rights licensed under this Agreement
infringes or otherwise violates the intellectual property rights of any Third
Party, then the Party against whom the claim is made shall promptly notify the
other Party to this Agreement of the claim and all reasonable details relating
to it. The Party against whom the claim is made shall

                                     -10-

<PAGE>

CONFIDENTIAL TREATMENT REQUESTED

have the right to defend the claim and the other Party shall reasonably
cooperate with the Party against whom the claim is made in the defense of the
claim, at the request and expense of the Party against whom the claim is made.
Each Party has the right to be represented by counsel of its own choice and at
its own expense in any proceedings.

         7.2 LIMITATIONS. TREGA HEREBY DISCLAIMS THE OBLIGATION TO INDEMNIFY
PURCHASER OR ITS CUSTOMERS AGAINST COSTS, LOSSES, DAMAGES, OR LIABILITIES
REGARDING CLAIMS OF INFRINGEMENT OR MISAPPROPRIATION BY THIRD PARTIES PERTAINING
TO TREGA MATERIALS OR USES THEREOF OR IMPROVEMENTS THERETO.

                                   ARTICLE 8

                        REPRESENTATIONS AND WARRANTIES

         Each Party hereby represents and warrants to the other Party as
follows:

         8.1 AUTHORIZATION AND ENFORCEMENT OF OBLIGATIONS. It (a) is duly
organized, validly existing and in good standing under the laws where organized
(b) has the requisite power and authority and the legal right to enter into this
Agreement and to perform its obligations hereunder, and (c) has taken all
necessary action on its part to authorize the execution and delivery of this
Agreement and the performance of its obligations hereunder. This Agreement has
been duly executed and delivered on behalf of such Party, and, subject to
satisfaction of the condition precedent at Article 1A, constitutes a legal,
valid and binding obligation, enforceable against such Party in accordance with
its terms.

         8.2 NO CONFLICT. The execution and delivery of this Agreement and the
performance of such Party's obligations hereunder (a) do not conflict with or
violate any requirement of applicable laws or regulations and (b) do not
conflict with, or constitute a default under, any contractual obligation of such
Party.

         8.3 TREGA MATERIALS. Trega represents and warrants that:

             8.3.1 Trega shall use reasonable endeavors to maximize the
diversity of the Subset Library Compounds supplied and offered to Purchaser
pursuant to this Agreement and such Subset Library Compounds shall be
representative of the developments made by Trega over the term of this
Agreement;

             8.3.2 all Trega Materials shall materially conform to the
specifications and certificates of analysis provided by Trega to Purchaser and
in any case shall conform to the specifications set out in Exhibit A;

             8.3.3 Trega is not at the Effective Date aware of any Third Party
intellectual property rights that may be infringed by the use of Trega
Materials, the [CONFIDENTIAL TREATMENT REQUESTED] or the Virtual Combinatorial
Libraries (in each case in accordance with this Agreement); and

                                     -11-

<PAGE>

CONFIDENTIAL TREATMENT REQUESTED

             8.3.4 Trega shall promptly notify Purchaser if it receives a
claim or assertion or otherwise becomes aware that the use of Trega Materials,
the [CONFIDENTIAL TREATMENT REQUESTED] or the Virtual Combinatorial Libraries
(in each case in accordance with this Agreement) infringes or otherwise violates
the intellectual property rights of any Third Party.

         8.4 DISCLAIMER OF WARRANTIES.

             8.4.1 NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A
REPRESENTATION MADE, OR WARRANTY GIVEN, BY TREGA THAT ANY PATENT WILL ISSUE
BASED UPON ANY PENDING PATENT APPLICATION WITHIN THE TREGA PATENTS, THAT ANY
PATENT WITHIN THE TREGA PATENTS WHICH ISSUES WILL BE VALID, OR THAT THE USE OF
ANY TREGA MATERIALS OR TREGA PATENTS WILL NOT INFRINGE THE PATENT OR PROPRIETARY
RIGHTS OF ANY OTHER PERSON.

             8.4.2 EXCEPT AS EXPRESSLY PROVIDED IN ARTICLE 8.3, TREGA
EXPRESSLY DISCLAIMS ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING
WITHOUT LIMITATION WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE, NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD
PARTIES AND WARRANTIES ARISING FROM A COURSE OF DEALING, USAGE OR TRADE
PRACTICES.

             8.4.3 IN NO EVENT WILL EITHER PARTY, OR, IN THE CASE OF TREGA,
ANY OF TREGA'S THIRD PARTY LICENSORS WHOSE TECHNOLOGY IS UTILISED IN PROVIDING
TREGA MATERIALS HEREUNDER, OR, IN THE CASE OF PURCHASER, ANY OF ITS CUSTOMERS,
BE LIABLE FOR ANY INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES RESULTING FROM
THE EXERCISE OF THE RIGHTS AND LICENCES GRANTED HEREUNDER OR THE USE OF THE
TREGA MATERIALS OR TREGA PATENT RIGHTS.

             8.4.4 NEITHER PARTY GIVES THE OTHER ANY WARRANTY AS TO THE
SUCCESS OF THE MARKETING TO BE CARRIED OUT PURSUANT TO ARTICLE 3.4 AND IN
PARTICULAR PURCHASER GIVES NO WARRANTY THAT ANY OR A PARTICULAR AMOUNT OF CLIENT
ACCESS FEES WILL BE PAYABLE TO TREGA PURSUANT TO THIS AGREEMENT.

                                     -12-

<PAGE>

CONFIDENTIAL TREATMENT REQUESTED

                                   ARTICLE 9

                              TERM AND TERMINATION

         9.1 EXPIRATION. Unless terminated earlier pursuant to Article 9.2 below
or extended by mutual agreement, the term of this Agreement expires on
[CONFIDENTIAL TREATMENT REQUESTED].

         9.2 TERMINATION FOR CAUSE. Either Party may terminate this Agreement
upon or after the breach of any material provision of this Agreement, if the
breaching Party has not cured such breach within ninety (90) days after notice
thereof from the other Party.

         9.3 EFFECT OF EXPIRATION AND TERMINATION. Expiration or termination of
this Agreement shall not relieve the Parties of any right or obligation accruing
prior to such expiration or termination. The provisions of Articles 1, 3.1, 3.2,
3.3, 4, 6, 7, 8, 9 and 14 shall survive the expiration or termination of this
Agreement.

         9.4 MARKETING MATERIALS. Following termination of this Agreement,
howsoever caused each party shall return to the other any marketing materials
received by it pursuant to Article 3.5.1 or 3.5.2, as applicable.

                                   ARTICLE 10

                                    INDEMNITY

         10.1 DIRECT INDEMNITY. Each Party shall indemnify and hold the other
Party, its Affiliates, directors, officers, employees, agents and stockholders
(and, in the case of the Purchaser, Customers) harmless and hereby forever
releases and discharges the other Party, its Affiliates, directors, officers,
employees, agents and stockholders from and against all losses, liabilities,
damages and expenses (including reasonable attorneys' fees and costs and amounts
paid in settlement) that the other Party, its Affiliates, directors, officers,
employees, agents and stockholders (and, in the case of the Purchaser,
Customers) may suffer or

                                     -13-
<PAGE>

incur as a result of any claims, demands, actions or other proceedings made or
instituted by a Third Party against any of them arising out of or relating to
(a) any breach by the indemnifying Party of its representations, warranties or
obligations under this Agreement, or (b) the negligence, recklessness, or
intentional acts or omissions in connection with the performance of obligations
hereunder by or on behalf of the indemnifying Party hereunder, but not to the
extent of the indemnified Party's negligence, recklessness, or intentional acts
or omissions.

         10.2 OTHER INDEMNITY. Purchaser shall indemnify and hold Trega, its
Affiliates, directors, officers, employees and agents harmless and hereby
forever releases and discharges Trega, its Affiliates, directors, officers,
employees and agents from and against all losses, liabilities, damages and
expenses (including reasonable attorneys' fees and costs) that Trega, its
Affiliates, directors, officers, employees and agents may suffer or incur as a
result of any claims, demands, actions or other proceedings made or instituted
by a Third Party against any of them arising out of or relating to (a) the use
by or on behalf of Purchaser or its Customers of Trega Materials, or (b) the
research, development, manufacture, storage, use, consumption, sale,
administration or advertisement of a Product (without regard to culpable
conduct) developed, designed, manufactured or commercialized by or on behalf of
Purchaser, or its Customers provided that this indemnity shall not apply to the
extent that such claims, demands, actions or other proceedings arise in
connection with a matter covered by Article 10.1.

         10.3 PROCEDURE. As a condition for obtaining indemnification hereunder,
a Party that intends to claim indemnification under this Article 10 (the
"Indemnitee") shall promptly notify the other Party (the "Indemnitor") of any
claim, demand, action or other proceeding for which the Indemnitee intends to
claim such indemnification, and the Indemnitor will have the right to
participate in, and, to the extent the Indemnitor so desires, jointly with any
other indemnitor similarly noticed, to assume the sole control over defense and
settlement thereof with counsel selected by the Indemnitor; PROVIDED, HOWEVER,
that the Indemnitee will have the right to retain its own counsel, with the fees
and expenses to be paid by the Indemnitor, if representation of the Indemnitee
by the counsel retained by the Indemnitor would be inappropriate due to actual
or potential conflict of interest between the Indemnitee and any other person
represented by such counsel in such proceedings. The Indemnitor shall not be
obliged to indemnify the Indemnitee under this Article 10 in respect of amounts
paid in settlement of any loss, claim, damage, liability or action unless such
settlement is effected or approved in advance by the Indemnitor. The failure to
deliver notice to the Indemnitor within a reasonable time after the commencement
of any such action, if prejudicial to its ability to defend such action,
relieves the Indemnitor of any liability to the Indemnitee under this Article
10, but the omission so to deliver notice to the Indemnitor will not relieve it
of any liability that it may have to the Indemnitee otherwise than under this
Article 10. The Indemnitor may not settle the action or otherwise consent to an
adverse judgment in such action that constitutes an admission of liability by
the Indemnitee without the express written consent of the Indemnitee. The
Indemnitee, its employees and agents, shall cooperate fully with the Indemnitor
and its legal representatives in the investigation of any action, claim or
liability covered by this indemnification.

         10.4 INSURANCE.

               10.4.1 Purchaser and Trega each shall maintain, through self
insurance or otherwise, insurance with respect to the research, development,
manufacture and sales of Products by Purchaser or Trega, as the case may be, in
such amount as Purchaser or Trega, respectively, customarily maintains covering
its similar activities. Trega and Purchaser, as applicable, shall maintain such
insurance for so long as each continues to conduct such research, development,
manufacture or sales, and thereafter for so long as Trega and Purchaser, as
applicable, each customarily maintains insurance for itself covering its similar
activities.

                                     -14-
<PAGE>

               10.4.2 Effective as of such time as a Product developed by
Purchaser enters human clinical trials, Purchaser, with respect to such Product,
at its sole cost and expense shall insure its activities under this Agreement
and obtain, keep in force and maintain insurance, including without limitation
product liability insurance, in amounts sufficient to cover its obligations
under this Article 10 and consistent with reasonable business practice in the
industry. Upon reasonable request, Purchaser shall furnish Trega with
certificates of insurance evidencing compliance with all requirements.

               10.4.3 Purchaser shall use reasonable commercial efforts to
negotiate the inclusion in contracts with Customers of a requirement for
Customers to obtain product liability insurance in respect of research,
development, manufacture or sale of Products developed by Customers.

                                   ARTICLE 11

                                  FORCE MAJEURE

         Neither Party shall be held liable or responsible to the other Party
nor be deemed to have defaulted under or breached this Agreement for failure or
delay in fulfilling or performing any term of this Agreement to the extent, and
for so long as, such failure or delay is caused by or results from causes beyond
the reasonable control of the affected Party including but not limited to fire,
floods, embargoes, war, acts of war (whether war be declared or not),
insurrections, riots, civil commotions, strikes, lockouts or other labor
disturbances, acts of God or acts, omissions or delays in acting by any
governmental authority or the other Party.

                                   ARTICLE 12

                                   ASSIGNMENT

         This Agreement may not be assigned or otherwise transferred, nor,
except as expressly provided hereunder, may any right or obligations hereunder
be assigned or transferred by either Party without the consent of the other
Party provided, however, that either Trega or Purchaser may, without such
consent, assign this Agreement and its rights and obligations hereunder to its
Affiliates or in connection with the transfer or sale of all or substantially
all of its business (or, in the case of Trega, all or substantially all of its
combinatorial chemistry business), or in the event of its merger or
consolidation or change in control or similar transaction. Any permitted
assignee shall assume all obligations of its assignor under this Agreement.

                                     -15-
<PAGE>

                                   ARTICLE 13

                                  SEVERABILITY

         Each Party hereby acknowledges that it does not intend to violate any
public policy, statutory or common laws, rules, regulations, treaty or decision
of any government agency or executive body thereof of any country or community
or association of countries. Should one or more provisions of this Agreement be
or become invalid, the Parties shall substitute, by mutual consent, valid
provisions for such invalid provisions which valid provisions in their economic
effect are sufficiently similar to the invalid provisions that it can be
reasonably assumed that the Parties would have entered into this Agreement with
such provisions. In case such provisions cannot be agreed upon, the invalidity
of one or several provisions of this Agreement shall not affect the validity of
this Agreement as a whole, unless the invalid provisions are of such essential
importance to this Agreement that it is to be reasonably assumed that the
Parties would not have entered into this Agreement without the invalid
provisions.

                                   ARTICLE 14

                                  MISCELLANEOUS

         14.1 NOTICES.

               14.1.1 Any consent, notice or report required or permitted to be
given or made under this Agreement by one of the Parties to the other will be in
writing, delivered personally, by courier, by facsimile (and promptly confirmed
by personal delivery, by courier or by air mail postage prepaid) or by air mail
postage prepaid addressed to such other Party at its address indicated below, or
to such other address as the addressee shall have last furnished in writing to
the addressor.

                           If to Trega:        Trega Biosciences, Inc.
                                               9880 Campus Point Drive
                                               San Diego, California 92121
                                               Attention: President

                          If to Purchaser:     Evotec BioSystems AG
                                               Schnackenburgallee 114
                                               22525 Hamburg Germany
                                               Attention: President

               14.1.2 Any notice delivered personally or by courier shall be
effective on delivery, any notice sent by facsimile shall be effective on the
next business day following the day of transmission and any notice sent by air
mail shall be effective on the tenth day after the day of posting (including the
day of posting).

                                     -16-
<PAGE>

         14.2 APPLICABLE LAW. This Agreement shall be governed by and construed
in accordance with the laws of the state of Delaware, United States, and the
parties hereby submit to the exclusive jurisdiction of the courts of the state
of Delaware.

         14.3 COMPLIANCE WITH APPLICABLE LAWS. Purchaser shall, and shall
request its Customers to, use reasonable efforts to comply with all applicable
laws, regulations and governmental orders in connection with their respective
activities related to this Agreement, including without limitation the research,
development, manufacture, use and sale of Products. Without limiting the
foregoing, Purchaser shall, and shall request its Customers to use reasonable
efforts to observe and comply with all applicable United States and other
foreign laws with respect to the transfer of Products and related technical data
to foreign countries.

         14.4 ENTIRE AGREEMENT. This Agreement contains the entire understanding
of the Parties with respect to the subject matter hereof and neither Party shall
be liable to the other for loss arising from or in connection with any
representations, agreements or undertakings not incorporated into this
Agreement. All express or implied agreements and understandings, either oral or
written, heretofore made are expressly superseded by this Agreement. This
Agreement may be amended, or any term hereof modified, only by a written
instrument duly executed by both Parties. The Parties agree to discuss annually
the evolution of Purchaser's Screening Services and to amend this agreement by
mutual agreement as necessary to reflect such evolution.

         14.5 HEADINGS. The captions to the several Articles hereof are not a
part of this Agreement, but are merely guides or labels to assist in locating
and reading the several Articles hereof.

         14.6 INDEPENDENT CONTRACTORS. It is expressly agreed that Trega and
Purchaser are independent contractors and that the relationship between the two
Parties does not constitute a partnership, joint venture or agency. Neither
Trega nor Purchaser has the authority to make any statements, representations or
commitments of any kind, or to take any action that binds the other, without the
prior written consent of the other Party.

         14.7 WAIVER. The waiver by either Party of any right in respect of the
failure to perform or breach by the other Party of this Agreement shall not be
deemed a waiver of any right in respect of any other breach or failure by said
other Party whether of a similar nature or otherwise.

         14.8 COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

                                     -17-
<PAGE>

         IN WITNESS WHEREOF, the Parties have executed this Agreement as of the
date first set forth above.

TREGA BIOSCIENCES, INC.               PURCHASER

By:      /s/ Mike Grey                By:      /s/ Karsten Henco
   -------------------------------        ------------------------------

Printed Name:      Mike Grey          Name:    Karsten Henco
             ---------------------         -----------------------------

Title:             CEO                Title:           CEO, CFO
      ----------------------------           ---------------------------

                                     -18-
<PAGE>

CONFIDENTIAL TREATMENT REQUESTED

                            EXHIBIT A: SPECIFICATIONS

[CONFIDENTIAL TREATMENT            Each Subset Library Compound purchased
REQUESTED] PER COMPOUND.           shall be shipped [CONFIDENTIAL TREATMENT
                                   REQUESTED], based on the [CONFIDENTIAL
                                   TREATMENT REQUESTED]. Subset Library
                                   Compounds shall be shipped [CONFIDENTIAL
                                   TREATMENT REQUESTED].

SUBSET LIBRARY SPECIFICATIONS      Subset Libraries must be [CONFIDENTIAL
                                   TREATMENT REQUESTED] using appropriate
                                   [CONFIDENTIAL TREATMENT REQUESTED] of the
                                   Subset Library Compounds
                                   [CONFIDENTIAL TREATMENT REQUESTED] Subset
                                   Library. Trega shall
                                   [CONFIDENTIAL TREATMENT REQUESTED] Subset
                                   Library [CONFIDENTIAL TREATMENT REQUESTED]
                                   Subset Library Compound. Such
                                   [CONFIDENTIAL TREATMENT REQUESTED] Subset
                                   Library Compounds.

                                   Trega shall
                                   [CONFIDENTIAL TREATMENT REQUESTED] Trega
                                   Materials
                                   [CONFIDENTIAL TREATMENT REQUESTED] which
                                   in respect of such shipment:

                                   -  [CONFIDENTIAL TREATMENT REQUESTED]
                                      the Subset Library Compounds
                                      [CONFIDENTIAL TREATMENT REQUESTED] and
                                      [CONFIDENTIAL TREATMENT REQUESTED] of
                                      the same

                                   - [CONFIDENTIAL TREATMENT REQUESTED] with
                                     the [CONFIDENTIAL TREATMENT REQUESTED] set
                                     out above; and

                                   - [CONFIDENTIAL TREATMENT REQUESTED] the
                                     [CONFIDENTIAL TREATMENT REQUESTED]used.

                                     -19-
<PAGE>

CONFIDENTIAL TREATMENT REQUESTED

                                    EXHIBIT B

                         OPTIONAL PRODUCTS AND SERVICES

[CONFIDENTIAL TREATMENT
REQUESTED]                         Trega grants to Purchaser the option to have
                                   Trega [CONFIDENTIAL TREATMENT REQUESTED]
                                   Subset Library Compounds.
                                   [CONFIDENTIAL TREATMENT REQUESTED]
                                   compounds will
                                   [CONFIDENTIAL TREATMENT REQUESTED] as the
                                   [CONFIDENTIAL TREATMENT REQUESTED] Subset
                                   Library Compound. If requested by
                                   Purchaser, Trega will
                                   [CONFIDENTIAL TREATMENT REQUESTED] to
                                   Purchaser
                                   [CONFIDENTIAL TREATMENT REQUESTED],
                                   PROVIDED HOWEVER, that at least
                                   [CONFIDENTIAL TREATMENT REQUESTED]is
                                   [CONFIDENTIAL TREATMENT REQUESTED] by
                                   Trega for
                                   [CONFIDENTIAL TREATMENT REQUESTED]. In any
                                   case, Purchaser may provide Trega with
                                   [CONFIDENTIAL TREATMENT REQUESTED] of all
                                   compounds under this Agreement for Trega's
                                   [CONFIDENTIAL TREATMENT REQUESTED]. Prior
                                   to Purchaser's
                                   [CONFIDENTIAL TREATMENT REQUESTED] a
                                   Subset Library, Purchaser and Trega will
                                   [CONFIDENTIAL TREATMENT REQUESTED] for
                                   Subset Library Compound
                                   [CONFIDENTIAL TREATMENT REQUESTED] should
                                   Purchaser decide not to
                                   [CONFIDENTIAL TREATMENT REQUESTED] Subset
                                   Library Compounds
                                   [CONFIDENTIAL TREATMENT REQUESTED].

                                     -20-
<PAGE>

CONFIDENTIAL TREATMENT REQUESTED

                                EXHIBIT C - FEES

PAYMENTS FOR SUBSET LIBRARIES.     Purchaser shall pay to Trega the sum of
                                   [CONFIDENTIAL TREATMENT REQUESTED] for
                                   [CONFIDENTIAL TREATMENT REQUESTED]
                                   Subset Library Compound purchased.
                                   Purchaser acknowledges that purchase of
                                   the minimum number of Subset Library
                                   Compounds in accordance with Article 2.2
                                   shall give rise to fees of
                                   [CONFIDENTIAL TREATMENT REQUESTED].

CLIENT ACCESS FEES                 The Client Access Fees payable pursuant to
                                   Article 3.2 shall be calculated
                                   [CONFIDENTIAL TREATMENT REQUESTED] a
                                   Subset Library Compound as follows:

                                   [CONFIDENTIAL TREATMENT REQUESTED]

                                   The [CONFIDENTIAL TREATMENT REQUESTED]
                                   Client Access Fee for a
                                   [CONFIDENTIAL TREATMENT REQUESTED] Subset
                                   Library Compound
                                   [CONFIDENTIAL TREATMENT REQUESTED],
                                   irrespective of
                                   [CONFIDENTIAL TREATMENT REQUESTED].

                                     -21-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}]]